Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

Triple negative breast cancer (TNBC) is an aggressive subset for which effective therapeutic approaches are needed. A significant proportion of TNBC patients harbor either germline or somatic mutations in BRCA1, or epigenetic silencing of BRCA1, which renders them deficient in DNA repair. Virtually...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Bing, Yu, Xin, Withers, Tracy, Gilleran, John, Yao, Ming, Foo, Tzeh Keong, Chen, Chunxia, Moore, Dirk, Lin, Yong, Kimball, S. David, Xia, Bing, Ganesan, Shridar, Carpizo, Darren R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465291/
https://www.ncbi.nlm.nih.gov/pubmed/30993195
http://dx.doi.org/10.1038/s41523-019-0110-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465291/
https://www.ncbi.nlm.nih.gov/pubmed/30993195
http://dx.doi.org/10.1038/s41523-019-0110-1

Ejemplares similares